Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options for patients with Waldenström’s macroglobulinemia (WM) who progress after standard chemotherapy and/or Bruton’s tyrosine kinase (BTK) inhibitors, highlighting the role of venetoclax in this patient population. Dr Castillo shares the findings from a study which evaluated the efficacy of venetoclax in previously-treated WM patients, including the progression-free survival (PFS) and very good partial response (VGPR) observed. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.